-
1.发明授权
公开(公告)号：EP1034254B1
公开(公告)日：2008-04-30
申请号：EP98957581.6
申请日：1998-11-02
CPC分类号： C12N7/00 , C12N2510/04 , C12N2760/16151
摘要： The present invention is directed to immortalized STAT1-deficient mammalian cell lines. STAT1 is a signal transducer and activator of transcription that becomes phosphorylated when cells are treated with type I or type II interferons and leads to induction of specific gene expression, resulting in establishment of the antiviral state and the other known biological responses to interferons, including the inhibition of cell proliferation. Cells which lack this gene product are useful for producing high titers of viral stocks, for producing recombinant viral vectors, for testing samples, especially clinical samples for the presence of virus and for screening candidate compounds or drugs for anti-viral activity.
-
公开(公告)号：EP1098961B1
公开(公告)日：2008-01-16
申请号：EP99927440.0
申请日：1999-06-11
申请人： MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK , Egorov, Andrej Y., Dr. , Muster, Thomas
发明人： EGOROV, Andrej Y., Dr. , MUSTER, Thomas , GARCIA-SASTRE, Adolfo , PALESE, Peter , BRANDT, Sabine
IPC分类号： C12N7/01 , C12N7/04 , C12N15/86 , A61K39/145 , A61K39/295
CPC分类号： C12N7/00 , A61K39/12 , A61K39/145 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2760/16121 , C12N2760/16122 , C12N2760/16132 , C12N2760/16134 , C12N2760/16161 , C12N2830/002 , Y02A50/412 , Y02A50/466
摘要： The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.
-
3.发明授权NOVEL METHODS AND INTERFERON DEFICIENT SUBSTRATES FOR THE PROPAGATION OF VIRUSES 有权新的方法和干扰素缺陷的底物，病毒的传播
公开(公告)号：EP1086207B1
公开(公告)日：2007-01-17
申请号：EP99927443.4
申请日：1999-06-11
CPC分类号： A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/155 , A61K39/17 , A61K39/205 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , A61K2039/543 , A61K2039/552 , A61K2039/572 , A61K2039/585 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2760/16121 , C12N2760/16122 , C12N2760/16132 , C12N2760/16134 , C12N2760/16143 , C12N2760/16151 , C12N2760/16161 , C12N2760/16162 , C12N2760/16171 , C12N2760/16221 , C12N2760/16222 , C12N2760/16232 , C12N2760/16234 , C12N2760/16243 , C12N2760/16251 , C12N2760/16262 , C12N2760/16271 , C12N2760/18022 , C12N2760/18034 , C12N2760/18122 , C12N2760/18134 , C12N2760/18522 , C12N2760/18534 , C12N2760/20222 , C12N2760/20234 , Y02A50/466
摘要： The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
-
公开(公告)号：EP1855713A2
公开(公告)日：2007-11-21
申请号：EP05856779.3
申请日：2005-06-01
申请人： MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK , The University of Kentucky Research Foundation
IPC分类号： A61K39/00 , A61K39/295 , A61K39/12 , A61K39/145 , C12N15/64 , C12N5/00 , A61K39/116
CPC分类号： C12N7/00 , A61K39/00 , A61K2039/5254 , A61K2039/5256 , C12N15/86 , C12N2760/16332 , C12N2760/16343 , C12N2760/16345 , C12N2760/16361 , C12N2810/6072
摘要： The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
-
公开(公告)号：EP1773384A2
公开(公告)日：2007-04-18
申请号：EP05856778.5
申请日：2005-06-01
申请人： THE MOUNT SINAI SCHOOL OF MEDICINE, OF THE CITY UNIVERSITY OF NEW YORK , ST. JUDE CHILDREN'S RESEARCH HOSPITAL , The United States of America as represented by the secretary of Agriculture
发明人： GARCIA-SASTRE, Adolfo , PALESE, Peter , LAGER, Kelly, M. , WEBSTER, Robert , RICHT, Juergen, A. , WEBBY, Richard, J.
IPC分类号： A61K39/00 , A61K39/12 , A61K39/145 , C12N15/64 , C12N5/00 , A61K39/116
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2760/16034 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171
摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
摘要翻译： 本发明一般涉及具有拮抗细胞干扰素（IFN）应答能力受损的减毒猪流感病毒，以及在疫苗和药物制剂中使用这种减毒病毒。 具体地，本发明涉及具有修饰的猪NS1基因的减毒猪流感病毒，其减少或消除NS1基因产物拮抗细胞IFN应答的能力。 这些病毒在体内复制，但表现出降低的复制，毒力和增加的衰减，因此非常适合用于活病毒疫苗和药物制剂。
-
6.发明公开CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS AND USES THEREOF 审中-公开CHIMÄREVIREN ALS NICHT-NATIVEOBERFLÄCHENPROTEINEUND IHRE VERWENDUNGEN
公开(公告)号：EP1962893A1
公开(公告)日：2008-09-03
申请号：EP06838693.7
申请日：2006-12-01
CPC分类号： C12N7/00 , A61K39/12 , A61K39/145 , A61K39/17 , A61K2039/5256 , A61K2039/541 , A61K2039/552 , A61K2039/70 , C07K14/005 , C07K2319/03 , C12N2760/16122 , C12N2760/16134 , C12N2760/16143 , C12N2760/16151 , C12N2760/16171 , C12N2760/18121 , C12N2760/18122 , C12N2760/18134 , C12N2760/18143 , C12N2760/18151 , C12N2760/18171
摘要： The present invention provides chimeric negative-stand RNA viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein. Such chimeric viruses induce an immune response against influenza virus and the infectious agent. The present invention also provides chimeric Newcastle Disease viruses (NDV) engineered to express and incorporate into their virions a fusion protein comprising the ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an NDV protein. Such chimeric viruses induce an immune response against NDV and the infectious agent.
摘要翻译： 本发明提供了通过使用本发明的单一嵌合病毒允许受试者例如禽类免疫两种感染因子的嵌合阴性立体RNA病毒。 特别地，本发明提供了嵌入式新城疫病毒（NDV），其被工程化以将其包含感染因子的蛋白质的胞外域和NDV蛋白的跨膜和胞质结构域的融合蛋白表达并并入其病毒粒子。 这种嵌合病毒诱导针对NDV和感染因子的免疫应答。
-
公开(公告)号：EP3248615A1
公开(公告)日：2017-11-29
申请号：EP17165017.9
申请日：2011-03-30
IPC分类号： A61K39/145 , A61P31/16 , C07K14/11
CPC分类号： C07K14/11 , A61K39/12 , A61K39/145 , A61K2039/5256 , A61K2039/5258 , C07K14/005 , C07K2319/00 , C12N2760/16022 , C12N2760/16034
摘要： Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same, nucleic acids encoding the same, and medical use of the same.
摘要翻译： 本文提供了流感血球凝集素茎结构域多肽，包含其的组合物，包含其的疫苗，编码其的核酸以及其医学用途。
-
8.发明授权
公开(公告)号：EP1114189B1
公开(公告)日：2009-12-16
申请号：EP99948214.4
申请日：1999-09-14
CPC分类号： C07K14/005 , A61K39/00 , A61K48/00 , A61K2039/523 , C12N2760/18122 , C12N2760/18134 , Y02A50/464
摘要： This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.
-
9.发明公开IMMORTALIZED, HOMOZYGOUS STAT1-DEFICIENT MAMMALIAN CELL LINES AND THEIR USES 有权永生化的纯合STAT1缺陷的哺乳动物细胞系用途
公开(公告)号：EP1034254A1
公开(公告)日：2000-09-13
申请号：EP98957581.6
申请日：1998-11-02
CPC分类号： C12N7/00 , C12N2510/04 , C12N2760/16151
摘要： The present invention is directed to immortalized STAT1-deficient mammalian cell lines. STAT1 is a signal transducer and activator of transcription that becomes phosphorylated when cells are treated with type I or type II interferons and leads to induction of specific gene expression, resulting in establishment of the antiviral state and the other known biological responses to interferons, including the inhibition of cell proliferation. Cells which lack this gene product are useful for producing high titers of viral stocks, for producing recombinant viral vectors, for testing samples, especially clinical samples for the presence of virus and for screening candidate compounds or drugs for anti-viral activity.
-
10.发明公开INFLUENZA VIRUS VACCINES AND USES THEREOF 审中-公开IMPFSTOFFE GEGEN DAS GRIPPEVIRUS UND IHRE VERWENDUNGEN
公开(公告)号：EP3009145A1
公开(公告)日：2016-04-20
申请号：EP15188497.0
申请日：2010-03-30
IPC分类号： A61K39/145 , C07K14/11
CPC分类号： A61K39/145 , A61K39/00 , A61K39/12 , A61K2039/5258 , A61K2039/53 , A61K2039/545 , A61K2039/55566 , A61K2039/58 , C07K14/005 , C12N2760/16034 , C12N2760/16122 , C12N2760/16134 , C12N2760/16222 , C12N2760/16234 , C12N2760/18143
摘要： The invention provides a polypeptide comprising an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment covalently linked to a linker of 1 to 50 heterologous residues that is in turn covalently linked to an HA1 C-terminal stem segment; said HA1 domain being in tertiary association with an influenza hemagglutinin HA2 domain. Further provided are a nucleic acid encoding the polypeptide of the invention, a cell expressing said nucleic acid, a virus comprising or expressing the polypeptide of the invention, an immunogenic composition comprising any of the above subject matter as well as its use in a method of immunizing a subject against an influenza virus disease or an influenza virus infection.
摘要翻译： 本发明提供了包含流感血凝素HA1结构域的多肽，其包含共价连接到1至50个异源残基的接头的HA1N末端茎段，所述接头又与HA1 C-末端茎段共价连接; 所述HA1结构域与流感血凝素HA2结构域结合在一起。 还提供了编码本发明多肽的核酸，表达所述核酸的细胞，包含或表达本发明多肽的病毒，包含任何上述主题的免疫原性组合物及其在以下方法中的用途： 免疫受试者免受流感病毒病或流感病毒感染。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.027 秒)
